Fig. 2From: Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutationSurvival analysis of OS in all patients. a The patients without BM had a longer OS than those with BM; b In the multivariable model, sex and whether developed BM were independently related to OS among all patientsBack to article page